Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)

• Nektar Therapeutics recently reported that The Lancet published peer-reviewed 16-week Phase 2b REZOLVE-AD data showing rezpegaldesleukin improved eczema severity, itch, quality-of-life outcomes, and key biomarkers in adults with moderate-to-severe atopic dermatitis, with all three dosing regimens outperforming placebo.
• The data, alongside a favorable safety profile and clear T-reg biomarker signal, underpins the ongoing global Phase 3 ZENITH AD program and broad autoimmune ambitions for this first-in-class IL-2 receptor–targeting biologic.
• We’ll now examine how these peer-reviewed Phase 2b results, especially the favorable safety profile, may influence Nektar’s existing investment narrative.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Nektar Therapeutics Investment Narrative Recap

To own Nektar Therapeutics, you need to believe rezpegaldesleukin can clear late‑stage trials and become a commercially relevant autoimmune franchise before the company’s cash burn forces painful financing. The Lancet REZOLVE‑AD data strengthen the near‑term catalyst around the ongoing ZENITH AD Phase 3 program by reinforcing efficacy, safety, and mechanism, but they do not remove the central risk of clinical or regulatory disappointment in a business still dependent on a single lead asset and running persistent losses.

Among recent developments, the initiation of the ZENITH AD Phase 3 program in July 2026 is most directly linked to this publication, as the Phase 2b data informed the chosen induction and maintenance regimens. This tight connection between peer‑reviewed efficacy and safety results and the Phase 3 trial design may influence how investors weigh the upside of potential approval against the continuing risks tied to high R&D spend, limited current revenue, and the prospect of further dilution.

Yet behind the strong trial headlines, investors should still pay close attention to the risk that ongoing losses and funding needs could...

Read the full narrative on Nektar Therapeutics (it's free!)

Nektar Therapeutics’ narrative projects $40.0 million revenue and $8.8 million earnings by 2029.

Uncover how Nektar Therapeutics' forecasts yield a $144.40 fair value, a 99% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$136,000,000 by 2029 and earnings turn positive, while also warning that payer pressure might squeeze future pricing power; this new REZOLVE‑AD publication could either reinforce that bullish view or prompt you to rethink how much optimism around rezpegaldesleukin’s trajectory really feels warranted.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com